Micardis

(Telmisartan)

ApprovedSmall molecule

Telmisartan is used to treat high blood pressure and to help prevent heart problems in people at high risk. It works by relaxing blood vessels so blood can flow more easily through your body.[2] Micardis is currently approved and in use across 34 indications[4].[1]

Micardis is one of 842 small molecule programs targeting Insulin resistance. It is currently in Approved.

Indications

158

Total Trials

Active Trials

841

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Insulin ResistanceActive, not recruiting

Coronary Artery DiseaseCompleted

Cardiovascular DiseaseActive, not recruiting

Endothelial DysfunctionApproved

Peripheral Arterial StenosisActive, not recruiting

AlbuminuriaActive, not recruiting

StrokeActive, not recruiting

Acute Coronary SyndromeActive, not recruiting

Alcoholic Fatty Liver DiseaseUnknown status

Diabetic NephropathyCompleted

Insulin ResistancePreclinical

Active, not recruiting

Coronary Artery DiseaseApproved

Completed

Cardiovascular DiseaseApproved

Active, not recruiting

Endothelial DysfunctionApproved

Approved

Peripheral Arterial StenosisPreclinical

Active, not recruiting

AlbuminuriaApproved

Active, not recruiting

StrokeApproved

Active, not recruiting

Acute Coronary SyndromeApproved

Active, not recruiting

Alcoholic Fatty Liver DiseaseApproved

Unknown status

Diabetic NephropathyApproved

Completed

Showing 10 of 34 indications

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

21 2

Micardis

Boehringer Ingelheim

Approved

1 3

Nizoral

WWim Janssens

Phase 3

21 4

Orgovyx

Sumitomo Pharma America, Inc.

Phase 3

12 5

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

10 6

Acetylsalicylic Acid

Bayer

Phase 3

2 7

Antiandrogen Therapy

UUniversity of Washington

Phase 3

9 8

Gallium Ga 68 Gozetotide

MMayo Clinic

Phase 3

3 9

Trexall

Jazz Pharmaceuticals

Preclinical

—10

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Not yet recruiting

Cardiotoxicity

NCT07370506

Q2 2027

Phase 1Recruiting

Prostate Cancer

NCT06168487

Q4 2027

Phase 1Not yet recruiting

Study completion

NCT07784608

Q2 2029

Phase 2Recruiting

Ovarian Cancer

NCT06815497

Clinical

Trials by Indication[1]

Hypertension24 trials

Effectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese Patients

Unknown status·SSaitama Medical University·N/A·NCT00288717·300 enrolled

Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02242318·440 enrolled

Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension

Completed·YYuhan Corporation·Phase 4·NCT03267329·80 enrolled

Show 21 more trials

Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02242838·6,336 enrolled

Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02242383·13,248 enrolled

Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT01316419·2,089 enrolled

Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02242812·24 enrolled

Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00281593·1,354 enrolled

Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02177409·431 enrolled

Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02177500·327 enrolled

Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT02242344·77 enrolled

TELSYS - TELmisartan Effectiveness in Isolated SYStolic Hypertension Versus Systolic/Diastolic Hypertension Patients Aged 55 or Older

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02242877·3,320 enrolled

CKD-828 Primary Hypertension Trial(Dose-selection)

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 2·NCT01128322·430 enrolled

Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02177422·489 enrolled

Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00860262·858 enrolled

Non-invasive Haemodynamic Assessment in Hypertension

Completed·MMilitary Institute od Medicine National Research Institute·N/A·NCT01996085·144 enrolled

Clinical Efficacy of Telmisartan in Reducing Cardiac Remodeling Among Obese Patients With Hypertension

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT03956823·300 enrolled

Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00326768·184 enrolled

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00281580·1,461 enrolled

Survey to Assess Why People Are Not Responding to Treatment in Hypertension

Completed· Bayer logo

Bayer··NCT01071681·1,589 enrolled

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00926289·894 enrolled

Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02177435·491 enrolled

Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02177461·374 enrolled

MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02177396·426 enrolled

Hypertensive14 trials

Replication of the TRANSCEND Antihypertensive Trial in Healthcare Claims Data

Completed·—··NCT04354376·40,048 enrolled

Pharmacovigilance and Patient Compliance in Hypertensive Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02200575·10,333 enrolled

J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT00659581·21,471 enrolled

Show 11 more trials

A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02242396·5,248 enrolled

Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02172586·363 enrolled

Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data

Completed·—··NCT04354350·63,744 enrolled

Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels

Terminated·RRWTH Aachen University·Phase 4·NCT00559286·40 enrolled

Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02242851·5,018 enrolled

Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients

Completed·LLudwig-Maximilians - University of Munich·Phase 3·NCT00560430·56 enrolled

Assessment of Compliance With Antihypertensive Telmisartan Therapy

Completed· Bayer logo

Bayer··NCT00470886·3,400 enrolled

COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-i Treatment Due to couGH in Slovakia

Completed· Bayer logo

Bayer··NCT01217879·980 enrolled

Telmisartan and Losartan in Hypertensive IGT

Completed·MMedical University of Graz·Phase 4·NCT00407862·24 enrolled

COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland

Completed· Bayer logo

Bayer··NCT01211171·2,498 enrolled

Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population

Completed·TThe George Institute for Global Health, China·N/A·NCT02255253·1,410 enrolled

ART14 trials

Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01344629·64 enrolled

Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02259790·30 enrolled

Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02261116·24 enrolled

Show 11 more trials

Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02259803·30 enrolled

Bioavailability of Lacidipine and Telmisartan Fixed Dose Combination Tablets Relative to Separate Tablets in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02209649·12 enrolled

Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02262598·30 enrolled

Bioequivalence of Telmisartan/ HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Male Volunteers II

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02262858·68 enrolled

Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02262624·36 enrolled

Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00146341·345 enrolled

Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02276391·64 enrolled

Comparative Study of the Effects of Telmisartan and Nebivolol

Unknown status·—·Phase 4·NCT02057328·80 enrolled

INvestigating TELmisartin Study

Terminated·UUniversity of Hawaii·Phase 2·NCT04715763·24 enrolled

Bioequivalence of Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional Telmisartan Tablet in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02261129·64 enrolled

Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01286558·225 enrolled

Essential Hypertension10 trials

Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02245464·13,066 enrolled

Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension

Completed·AAddpharma Inc.·Phase 2·NCT04218552·176 enrolled

Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00257491·29 enrolled

Show 7 more trials

Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02238262·2,318 enrolled

Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02183701·715 enrolled

3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00153049·583 enrolled

Micardis® in Patients With Essential Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02187705·1,688 enrolled

Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00144222·218 enrolled

Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®

Completed· Bayer logo

Bayer··NCT00927537·2,052 enrolled

Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02206659·20 enrolled

Female7 trials

Steady State Pharmacokinetics of Telmisartan, Ramipril or the Combination Following Repeated Oral Doses to Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02215005·42 enrolled

Bioequivalence of Telmisartan / Ramipril Fixed Dose Combination Compared With the Monocomponents Given Concomitantly to Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02214979·84 enrolled

Bioequivalence of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02193308·84 enrolled

Show 4 more trials

Bioequivalence Study of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02259829·84 enrolled

Tolerability and Pharmacokinetics of Lacidipine With and Without the Co-administration of Telmisartan in Female and Male Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02203500·26 enrolled

Bioequivalence of Telmisartan/g Ramipril Fixed Dose Combination Compared With the Monocomponents Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02214992·84 enrolled

Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02262793·24 enrolled

58 more indications

Interaction6 trials

Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers

Completed· Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.·Phase 1·NCT02933658·71 enrolled

Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)

Completed·YYuhan Corporation·Phase 1·NCT02152969·66 enrolled

CKD-828 Drug Interaction Study (Telmisartan)

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 1·NCT01356017·32 enrolled

Show 3 more trials

A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide

Completed· IlDong Pharmaceutical Co Ltd logo

IlDong Pharmaceutical Co Ltd·Phase 1·NCT03889145·30 enrolled

Pharmacokinetic Interactions and Safety Study of Telmisartan and Chlorthalidone

Completed·HHanAll BioPharma Co., Ltd.·Phase 1·NCT01806363·60 enrolled

The Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers

Completed·YYuhan Corporation·Phase 1·NCT02233218·60 enrolled

Metabolic Syndrome4 trials

Telmisartan and Renal Perfusion in Patients With Metabolic Syndrome

Completed·UUniversity of Erlangen-Nürnberg Medical School·Phase 3·NCT00452192·30 enrolled

The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome

Completed·—·Phase 4·NCT00926341·110 enrolled

A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome

Unknown status· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 4·NCT05843162·116 enrolled

Show 1 more trial

A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome

Terminated·YYuhan Corporation·Phase 4·NCT02968160·55 enrolled

Efficacy and Safety4 trials

Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine

Completed·AAddpharma Inc.·Phase 3·NCT04158076·131 enrolled

Efficacy and Safety of Telmisartan Compared With Losartan

Recruiting· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 4·NCT06431477·98 enrolled

Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal

Completed· Novartis logo

Novartis·Phase 4·NCT00865020·822 enrolled

Show 1 more trial

Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan

Completed·AAddpharma Inc.·Phase 3·NCT03872232·180 enrolled

Trial4 trials

INTERVENCION Trial

Completed·PPrevencion·Phase 4·NCT02373163·166 enrolled

Telmisartan 80mg Non-responder Trial

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01222520·174 enrolled

Filtered Trial for Telmisartan 40mg Non-responder

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00550953·314 enrolled

Show 1 more trial

CKD-828 Telmisartan Non-Responder Trial

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 3·NCT01426100·183 enrolled

COVID-194 trials

Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19

Terminated·UUniversity Hospital, Strasbourg, France·Phase 3·NCT04359953·16 enrolled

Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial

Completed·AANRS, Emerging Infectious Diseases·Phase 2/3·NCT04466241·294 enrolled

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

Terminated·UUniversity of British Columbia·Phase 3·NCT04606563·341 enrolled

Show 1 more trial

Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation

Completed·UUniversity Hospital, Bordeaux·Phase 2/3·NCT04356495·412 enrolled

Hyperlipidemia3 trials

Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia

Completed·YYuhan Corporation·Phase 3·NCT01914432·210 enrolled

Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia

Completed· IlDong Pharmaceutical Co Ltd logo

IlDong Pharmaceutical Co Ltd·Phase 3·NCT03566316·134 enrolled

Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia

Unknown status· IlDong Pharmaceutical Co Ltd logo

IlDong Pharmaceutical Co Ltd·Phase 3·NCT02087540·310 enrolled

Cardiovascular2 trials

SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00274105·22 enrolled

HIGH Altitude CArdiovascular REsearch in the ANDES

Completed·IIstituto Auxologico Italiano·Phase 4·NCT01830530·100 enrolled

Polycystic Kidney Disease2 trials

HALT Progression of Polycystic Kidney Disease Study B

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT01885559·486 enrolled

HALT Progression of Polycystic Kidney Disease Study A

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00283686·558 enrolled

Heart Failure2 trials

Telmisartan Versus Enalapril in Heart Failure With Reduced Ejection Fraction Patients With Moderately Impaired Kidney Functions

Completed·—·N/A·NCT04736329·107 enrolled

Telmisartan in Haemodialysis Patients With Chronic Heart Failure

Completed·UUniversity of Campania Luigi Vanvitelli·Phase 4·NCT00490958·351 enrolled

CKD2 trials

CKD-828 (80/5mg) Pharmacokinetic Study

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 1·NCT02250833·69 enrolled

CKD-828 (80/5mg) Pharmacokinetic Study

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 1·NCT02358824·48 enrolled

Nephropathy2 trials

1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00153023·885 enrolled

A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00168857·860 enrolled

Blood Pressure2 trials

Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT00946829·18,299 enrolled

Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control.

Completed· Bayer logo

Bayer·Phase 4·NCT00750113·405 enrolled

Oral2 trials

Relative Oral Bioavailability of Telmisartan / Hydrochlorothiazide (HCTZ) Fixed Dose Combination (FDC) Compared With Its Monocomponents in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02187523·32 enrolled

Bioequivalence of Telmisartan Film-coated Tablet Compared With the Conventional Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02263989·30 enrolled

Tics2 trials

Pharmacokinetics of Telmisartan Alone and in Combination With Amlodipine in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02259816·38 enrolled

Tolerability and Pharmacokinetics of Telmisartan in Combination With Lacidipine in Healthy Male Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02218684·27 enrolled

Diabetes2 trials

DETAIL Study: Diabetes Exposed to Telmisartan and Enalapril

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00274118·250 enrolled

Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes

Completed·KKorea University Anam Hospital·Phase 4·NCT00599885·72 enrolled

Chronic Kidney Disease2 trials

HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria

Unknown status·YYuhan Corporation·Phase 4·NCT03550859·374 enrolled

A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD

Enrolling by invitation·BBaylor Research Institute·Approved·NCT07547878·64 enrolled

Dilation1 trial

Telmisartan, Amlodipine and Flow Mediated Dilation

Unknown status·JJohannes Gutenberg University Mainz·Phase 4·NCT01180205·576 enrolled

Peripheral Artery Disease1 trial

Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease

Completed·NNorthwestern University·N/A·NCT02593110·114 enrolled

Angiotensin Receptor Blockers1 trial

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02215733·1,165,781 enrolled

Endothelial Dysfunction1 trial

Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00240422·96 enrolled

Atrial Fibrillation1 trial

Nifedipine vs Telmisartan on Prevention of Atrial Fibrillation (AF) Recurrence in Hypertensive Patients With AF

Completed·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 4·NCT01435161·160 enrolled

Adult1 trial

Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fasting State

Completed·PPharmtechnology LLC·Phase 1·NCT03705533·26 enrolled

Safety and Efficacy1 trial

Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00274612·801 enrolled

Type 2 Diabetes Mellitus1 trial

A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

Completed· Takeda logo

Takeda·Phase 4·NCT02079805·33 enrolled

Statin1 trial

Pharmacokinetics of Simvastatin and Its Metabolite Simvastatin Acid With and Without Concomitant Administration of Telmisartan in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02187536·16 enrolled

Hypercholesterolemia1 trial

Combination of Telmisartan and Simvastatin in the Treatment of Hypertension and Hypercholesterolemia

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00316095·1,695 enrolled

Ovarian Cancer1 trial

Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

Recruiting·UUnknown Sponsor·Phase 2·NCT06815497·33 enrolled

HIV infection1 trial

Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV Infection

Completed·YYale University·Phase 1·NCT02170246·21 enrolled

Cardiovascular Events1 trial

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00153101·31,546 enrolled

Acute Coronary Syndrome1 trial

Telmisartan Versus Ramipril After Acute Coronary Syndrome

Unknown status·—·Phase 4·NCT00702936·50 enrolled

Cardiotoxicity1 trial

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Not yet recruiting·TTanta University·Phase 1/2·NCT07370506·36 enrolled

Alzheimer's Disease1 trial

Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients

Terminated·SSunnybrook Health Sciences Centre·Phase 2·NCT02085265·23 enrolled

Alcoholic Fatty Liver Disease1 trial

Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease

Unknown status·NNanfang Hospital, Southern Medical University·Phase 4·NCT02213224·180 enrolled

Albuminuria1 trial

Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)

Withdrawn·SSteno Diabetes Center Copenhagen·Phase 4·NCT03504566

Sepsis1 trial

Antihypertensive Medications and the Risk of Sepsis

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02248896·1,129,062 enrolled

Efficacy1 trial

PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00274599·812 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

Terminated·HHackensack Meridian Health·N/A·NCT02338232·32 enrolled

Kidney Transplant1 trial

Telmisartan Versus Losartan in Kidney Transplantation

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT01224860·20 enrolled

Double-blind1 trial

A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients

Completed·TThird Military Medical University·Phase 4·NCT00538486·360 enrolled

Bicuspid aortic valve1 trial

Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study)

Terminated·HHamilton Health Sciences Corporation·Phase 3·NCT01202721·85 enrolled

Abdominal Aortic Aneurysm1 trial

Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms

Completed·PPalo Alto Veterans Institute for Research·Phase 4·NCT01683084·22 enrolled

HIV1 trial

HIV and Fat Accumulation

Completed·UUniversity of California, Los Angeles·Phase 2·NCT01088295·35 enrolled

Respiratory Failure1 trial

Telmisartan in Respiratory Failure Due to COVID-19

Completed·AAbraham Edgar Gracia-Ramos·Phase 2·NCT04510662·66 enrolled

Parkinson's Disease1 trial

Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial

Recruiting·UUniversity College, London·Phase 3·NCT07207057·1,200 enrolled

Coronary Artery Disease1 trial

Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00274144·42 enrolled

SARS CoV 2 Infection1 trial

Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection

Unknown status·AANRS, Emerging Infectious Diseases·Phase 2/3·NCT04920838·600 enrolled

Diabetic Nephropathy1 trial

INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00153088·527 enrolled

Complication1 trial

Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients

Terminated·UUniversity of Hawaii·Phase 2·NCT04360551·24 enrolled

Obstructive Sleep Apnea1 trial

Improving 24-hour Blood Pressure in Obstructive Sleep Apnea

Withdrawn·UUniversity of British Columbia·Phase 1·NCT04021550

Neuropathic Pain1 trial

Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel)

Completed·—·Phase 2·NCT05322889·35 enrolled

Schizophrenia1 trial

Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia

Completed·UUniversity of Massachusetts, Worcester·Phase 4·NCT00981526·66 enrolled

Atorvastatin1 trial

To Evaluate the Drug-drug Interaction Between Telmisartan and Atorvastatin in Healthy Male Volunteers

Completed·SSamil Pharmaceutical Co., Ltd.·Phase 1·NCT02579356·48 enrolled

Heart Disease1 trial

A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease

Completed·UUniversity of California, Los Angeles·Phase 2·NCT01578772·17 enrolled

AIDS1 trial

Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01928927·58 enrolled

Insulin resistance1 trial

Treatment of Insulin Resistance in Hypertensive, Obese Adolescents

Terminated·SStanford University·N/A·NCT00185705·30 enrolled

Clopidogrel1 trial

Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02262650·24 enrolled

Prostate Cancer1 trial

Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer

Recruiting·UUnknown Sponsor·Phase 1·NCT06168487·36 enrolled

Unspecified3 trials

Health Evaluation in African Americans Using RAS Therapy

Completed·EEmory University·Phase 1/2·NCT02471833·61 enrolled

Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT01050062·1,452 enrolled

An Open-label, Fixed-sequence, 3-period Clinical Trial to Evaluate the Drug-drug Interactions of Co-administered 'HUC2-744-A' and 'HUC2-744-B' in Healthy Adult Volunteers

Not yet recruiting·HHuons Co., Ltd.·Phase 1·NCT07784608·28 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 4, 2000

MICARDIS

NDA NDA020850

Nov 17, 2000

MICARDIS HCT

NDA NDA021162

Apr 19, 2004

MICARDIS HCT

NDA NDA021162

Sep 2, 2005

MICARDIS HCT

NDA NDA021162

Feb 27, 2007

MICARDIS HCT

NDA NDA021162

Aug 11, 2009

MICARDIS HCT

NDA NDA021162

Aug 11, 2009

MICARDIS HCT

NDA NDA021162

May 12, 2011

MICARDIS HCT

NDA NDA021162

May 12, 2011

MICARDIS HCT

NDA NDA021162

Jan 19, 2012

MICARDIS HCT

NDA NDA021162

Jan 20, 2012

MICARDIS HCT

NDA NDA021162

Oct 24, 2012

MICARDIS HCT

NDA NDA021162

Dec 12, 2014

MICARDIS HCT

NDA NDA021162

Jan 12, 2016

MICARDIS HCT

NDA NDA021162

Feb 1, 2018

MICARDIS HCT

NDA NDA021162

Aug 20, 2020

MICARDIS HCT

NDA NDA021162

Dec 19, 2022

MICARDIS HCT

NDA NDA021162

Sources

References

[1]
ClinicalTrials.gov — 158 trial records for Telmisartan. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Micardis drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Telmisartan compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Telmisartan. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021162). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Type-1 Angiotensin II Receptor Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Boehringer Ingelheim

Micardis

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q4 2027

Q2 2029

Trials by Indication[1]

Hypertension24 trials

Hypertensive14 trials

ART14 trials

Essential Hypertension10 trials

Female7 trials

Interaction6 trials

Metabolic Syndrome4 trials

Efficacy and Safety4 trials

Trial4 trials

COVID-194 trials

Hyperlipidemia3 trials

Cardiovascular2 trials

Polycystic Kidney Disease2 trials

Heart Failure2 trials

CKD2 trials

Nephropathy2 trials

Blood Pressure2 trials

Oral2 trials

Tics2 trials

Diabetes2 trials

Chronic Kidney Disease2 trials

Dilation1 trial

Peripheral Artery Disease1 trial

Angiotensin Receptor Blockers1 trial

Endothelial Dysfunction1 trial

Atrial Fibrillation1 trial

Adult1 trial

Safety and Efficacy1 trial

Type 2 Diabetes Mellitus1 trial

Statin1 trial

Hypercholesterolemia1 trial

Ovarian Cancer1 trial

HIV infection1 trial

Cardiovascular Events1 trial

Acute Coronary Syndrome1 trial

Cardiotoxicity1 trial

Alzheimer's Disease1 trial

Alcoholic Fatty Liver Disease1 trial

Albuminuria1 trial

Sepsis1 trial

Efficacy1 trial

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Kidney Transplant1 trial

Double-blind1 trial

Bicuspid aortic valve1 trial

Abdominal Aortic Aneurysm1 trial

HIV1 trial

Respiratory Failure1 trial

Parkinson's Disease1 trial

Coronary Artery Disease1 trial

SARS CoV 2 Infection1 trial

Diabetic Nephropathy1 trial

Complication1 trial

Obstructive Sleep Apnea1 trial

Neuropathic Pain1 trial

Schizophrenia1 trial

Atorvastatin1 trial

Heart Disease1 trial

AIDS1 trial

Insulin resistance1 trial

Clopidogrel1 trial

Prostate Cancer1 trial

Unspecified3 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News